| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000004488 |
| Receipt No. | R000005368 |
| Official scientific title of the study | Randomized evaluation of the beneficial effect of Livact in patients with heart failure complicated by hypoalbuminemia |
| Date of disclosure of the study information | 2010/11/08 |
| Last modified on | 2017/05/19 (Ver. 7) |
| Basic information | ||
| Official scientific title of the study | Randomized evaluation of the beneficial effect of Livact in patients with heart failure complicated by hypoalbuminemia | |
| Title of the study (Brief title) | Livact Heart Failure Trial | |
| Region |
|
|
| Condition | ||
| Condition | heart failure patients complicated by hypoalbuminemia | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the beneficial effect of Livact for heart failure patients complicated by hypoalbuminemia |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Serum albumine
Cardiothoracic ratio (CTR) |
| Key secondary outcomes | Duration of admission, Hospitalization cost, Amount of food intake, Performance status, BNP, Amino acid fraction, Racio of mercapto albumin, Left ventricular ejection fraction |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | YES |
| Dynamic allocation | YES |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intervention
Conventional therapy plus Livact 12g t.i.d. 4 weeks or until discharge |
|
| Interventions/Control_2 | Control
Conventional therapy only |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Hospitalized patients due to exacerbation of heart failure
2) Hypoalbuminemia in two discrete blood test during hospitalization 3) over 20 years old |
|||
| Key exclusion criteria | 1) Renal dysfunction (BUN over 40mg/dl or Cre over 2.0mg/dl
2) Nephrotic syndrome, or urine protein over 3+ 3) HbA1c over 8.0% 4) Liver cirrhosis 5) Patients with malignancy 6) Patients with abnormal branched-chain amino acid metabolism 7) Ventricular arrhythmia 8) Patients who need ventilator support. 9) Severe infectious disease 10) Patients who are enrolled in another clinical trial |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Masafumi Watanabe |
| Organization | University of Tokyo Hospital |
| Division name | Department of Cardiovascular Medicine |
| Address | Hongo 7-3-1, Bunkyo-ku, Tokyo, Japan |
| TEL | 03-3815-5411 |
| masafumi-tky@umin.net | |
| Public contact | |
| Name of contact person | Masafumi Watanabe |
| Organization | University of Tokyo Hospital |
| Division name | Department of Cardiovascular Medicine |
| Address | Hongo 7-3-1, Bunkyo-ku, Tokyo, Japan |
| TEL | 03-3815-5411 |
| Homepage URL | |
| masafumi-tky@umin.net | |
| Sponsor | |
| Institute | University of Tokyo Hospital, Departement of Cardiovascular Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ajinomoto Pharmaceuticals Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000005368 |